The Injective (INJ) token has risen over 30% following a breakout from a bullish cup-and-handle pattern, with analysts projecting a price target near $14. Injective leads major blockchains in revenue relative to fully diluted market cap, outperforming Solana, Arbitrum, Ethereum, Sui, and Avalanche. This strong revenue supports a monthly community buyback program that permanently reduces token supply, potentially boosting value. With new tokenization initiatives and product launches planned, Injective's revenue and price momentum are expected to continue.
Injective (INJ) has surged 30.11% in one day on Pluang, reaching Rp167.411 as of Oct 16, 2026 17:31 WIB. Despite the strong price rally, sell orders dominate at 79% of Pluang's order activity. The typical holding period for INJ on Pluang is 38 days, indicating moderate-term investor interest.
Injective (INJ) surged 27.8% to $9.27, leading Friday's crypto gainers while Bitcoin remained stable around $82,197. This sharp rise highlights growing investor interest in altcoins despite Bitcoin dominance holding steady at 59.3%. Market sentiment ...
Injective (INJ) has surged 25% in 24 hours and over 70% in the past month, driven by strong spot and derivatives demand. The token's revenue-to-fully diluted value ratio is notably higher than competitors like Arbitrum and Ethereum, indicating solid ...
Injective's token price surged over 8% on October 16, reaching $9.35, driven by increased trading volume and positive market sentiment from new institutional developments. Key factors include Gulf Labs joining as an institutional validator and ongoin...
Injective (INJ) surged 24.46% to $9.13 on October 16, 2026, driven by sustained token withdrawals from exchanges and a major institutional data migration by Pineapple Financial. Despite high reported trading volumes, much of the on-chain activity is ...
Akedo (AKE) surged 16.09% to $0.0316, driven by growing investor interest in gaming-related crypto projects, pushing its market cap to $719.91 million. Meanwhile, Bitway (BTW) dropped sharply by 23.10% to $1.81 amid regulatory concerns, highlighting ...
